Riptylimab for the Treatment of Optic Neuritis and Myelitis Spectrum Diseases

Clinical trial NCT07685678 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07685678
Sponsor: Zhongming Qiu
Status: NOT_YET_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Neuromyelitis Optica Spectrum Disease (NMOSD)Ripertamab

Start date: 2026-07-15
Primary completion: 2030-01-01
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.